Skip to main content
Fig. 5 | Acta Neuropathologica Communications

Fig. 5

From: MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value

Fig. 5

ROC-curves. Four combinations of CpG sites were investigated. MC1 was chosen according to the CpG sites that are commonly analyzed by the Therascreen pyrosequencing kit and often used in clinical practice. The other CpG site combinations MC2-MC4 were chosen based on features observed in the correlation analysis, Random Forest analysis and ROC analysis for single CpGs. The 2 missing values in the data set were imputed based on MissForest algorithm. In A only patients treated with temozolomide were investigated. No major changes in the area under the curve (AUC) were observed, ranging from 0.867 (MC1) to 0.896 (MC3). In B all patients from this cohort were investigated. Also here there were no major differences observed ranging from MC1 with an AUC of 0.786 to MC2 with an AUC of 0.826

Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us